Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06448208 | RECRUITING | Neuroendocrine Tumors

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Sponsor:

Memorial Sloan Kettering Cancer Center

Brief Summary:

People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new criteria for doctors to use when evaluating these PET scans. Researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. Researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.

Condition or disease

Neuroendocrine Tumors

Intervention/treatment

positron emission tomography (PET) scans

Study Type : OBSERVATIONAL
Estimated Enrollment : 50 participants
Official Title : Definition of PET REsponSe CrItEria for Neuroendocrine Tumors (PRESCIENT)
Actual Study Start Date : 2024-06-03
Estimated Primary Completion Date : 2026-06
Estimated Study Completion Date : 2026-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Subjects affected by histologically proven, somatostatin-receptor positive, metastatic or inoperable well-differentiated G1, G2 or G3 neuroendocrine tumors (NETs) candidate to receive PRRT with 177Lu-DOTATATE per standard of care.
  • Inclusion Criteria
    • 1. Histologically proven or cytologically confirmed, metastatic or inoperable NETs
    • 2. Measurable disease as defined by RECIST 1.1.
    • 3. Overexpression of somatostatin receptors of the target lesions at somatostatin receptor imaging (68Ga-DOTATATE or 64Cu-DOTATATE PET/CT) with SUV of lesions greater than normal liver at least in 1 metastasis.
    Exclusion Criteria
    • 1. Neuroendocrine Carcinoma), small and large cell type; MIxed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN).
    • 2. Presence of somatostatin receptor negative lesions.
    • Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

    Location Details

    NCT06448208

    Please Choose a site

    How to Participate

    Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

    Locations

    RECRUITING

    United States, New York

    Memorial Sloan Kettering Cancer Center

    New York, New York, United States, 10065